Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: An examination of citalopram in the STAR*D study

Sidney Zisook, Madhukar H. Trivedi, Diane Warden, Barry Lebowitz, Michael E. Thase, Jonathan W. Stewart, Christine Moutier, Maurizio Fava, Stephen R. Wisniewski, James Luther, A. John Rush

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Background: Untreated major depressive disorder (MDD) is a major risk factor for suicide, but some data suggest antidepressants may be associated with increased suicidal ideation (SI) in some depressed patients. The purpose of this study was to determine whether, and in whom, treatment of MDD is associated with increased or emergent SI. Methods: Patients were treated with Citalopram, 10-60 mg/day for 12-14 weeks. A score > 0 on Item 12 of the Quick Inventory of Depressive Symptomatology - Self-Report indicated the presence of SI. Worsening was defined by a ≥ 1 point increase. Emergent SI was defined by an increase from 0 at baseline to ≥ 1 during treatment. Results: Of the 1909 participants with baseline SI, 57% experienced improvement in SI by their first post-baseline visit and 5% worsened. By the final visit, 74% experienced improvement and 4% worsened. Of 1721 participants without baseline SI, 7% experienced emergence by the first postbaseline visit. Of these, 63% had no SI at their final visit. Major risk factors for treatment-emergent SI at the first treatment visit were drug abuse, severe depression and melancholic features. Limitations: Main limitations are lack of a comparison group to help pinpoint whether citalopram treatment added risk or protection, a placebo group to determine whether changes in SI were related to illness factors, medication effects or other factors, and more detailed and validated measures of SI. Conclusions: SI and behaviors, core features of MDD, wax and wane in intensity before, during, and perhaps after treatment. It is clinically important to understand risk factors, maintain careful surveillance and treat as vigorously as necessary to attain remission.

Original languageEnglish (US)
Pages (from-to)63-73
Number of pages11
JournalJournal of Affective Disorders
Volume117
Issue number1-2
DOIs
StatePublished - Sep 2009

Fingerprint

Suicidal Ideation
Citalopram
Depression
Major Depressive Disorder
Therapeutics
Waxes
Self Report
Suicide
Antidepressive Agents
Substance-Related Disorders

Keywords

  • Major depressive disorder
  • SSRI
  • Suicidal ideation
  • Suicide
  • Treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression : An examination of citalopram in the STAR*D study. / Zisook, Sidney; Trivedi, Madhukar H.; Warden, Diane; Lebowitz, Barry; Thase, Michael E.; Stewart, Jonathan W.; Moutier, Christine; Fava, Maurizio; Wisniewski, Stephen R.; Luther, James; Rush, A. John.

In: Journal of Affective Disorders, Vol. 117, No. 1-2, 09.2009, p. 63-73.

Research output: Contribution to journalArticle

Zisook, Sidney ; Trivedi, Madhukar H. ; Warden, Diane ; Lebowitz, Barry ; Thase, Michael E. ; Stewart, Jonathan W. ; Moutier, Christine ; Fava, Maurizio ; Wisniewski, Stephen R. ; Luther, James ; Rush, A. John. / Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression : An examination of citalopram in the STAR*D study. In: Journal of Affective Disorders. 2009 ; Vol. 117, No. 1-2. pp. 63-73.
@article{c91b65cad33443cb81d2e3bff9a16ce4,
title = "Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: An examination of citalopram in the STAR*D study",
abstract = "Background: Untreated major depressive disorder (MDD) is a major risk factor for suicide, but some data suggest antidepressants may be associated with increased suicidal ideation (SI) in some depressed patients. The purpose of this study was to determine whether, and in whom, treatment of MDD is associated with increased or emergent SI. Methods: Patients were treated with Citalopram, 10-60 mg/day for 12-14 weeks. A score > 0 on Item 12 of the Quick Inventory of Depressive Symptomatology - Self-Report indicated the presence of SI. Worsening was defined by a ≥ 1 point increase. Emergent SI was defined by an increase from 0 at baseline to ≥ 1 during treatment. Results: Of the 1909 participants with baseline SI, 57{\%} experienced improvement in SI by their first post-baseline visit and 5{\%} worsened. By the final visit, 74{\%} experienced improvement and 4{\%} worsened. Of 1721 participants without baseline SI, 7{\%} experienced emergence by the first postbaseline visit. Of these, 63{\%} had no SI at their final visit. Major risk factors for treatment-emergent SI at the first treatment visit were drug abuse, severe depression and melancholic features. Limitations: Main limitations are lack of a comparison group to help pinpoint whether citalopram treatment added risk or protection, a placebo group to determine whether changes in SI were related to illness factors, medication effects or other factors, and more detailed and validated measures of SI. Conclusions: SI and behaviors, core features of MDD, wax and wane in intensity before, during, and perhaps after treatment. It is clinically important to understand risk factors, maintain careful surveillance and treat as vigorously as necessary to attain remission.",
keywords = "Major depressive disorder, SSRI, Suicidal ideation, Suicide, Treatment",
author = "Sidney Zisook and Trivedi, {Madhukar H.} and Diane Warden and Barry Lebowitz and Thase, {Michael E.} and Stewart, {Jonathan W.} and Christine Moutier and Maurizio Fava and Wisniewski, {Stephen R.} and James Luther and Rush, {A. John}",
year = "2009",
month = "9",
doi = "10.1016/j.jad.2009.01.002",
language = "English (US)",
volume = "117",
pages = "63--73",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression

T2 - An examination of citalopram in the STAR*D study

AU - Zisook, Sidney

AU - Trivedi, Madhukar H.

AU - Warden, Diane

AU - Lebowitz, Barry

AU - Thase, Michael E.

AU - Stewart, Jonathan W.

AU - Moutier, Christine

AU - Fava, Maurizio

AU - Wisniewski, Stephen R.

AU - Luther, James

AU - Rush, A. John

PY - 2009/9

Y1 - 2009/9

N2 - Background: Untreated major depressive disorder (MDD) is a major risk factor for suicide, but some data suggest antidepressants may be associated with increased suicidal ideation (SI) in some depressed patients. The purpose of this study was to determine whether, and in whom, treatment of MDD is associated with increased or emergent SI. Methods: Patients were treated with Citalopram, 10-60 mg/day for 12-14 weeks. A score > 0 on Item 12 of the Quick Inventory of Depressive Symptomatology - Self-Report indicated the presence of SI. Worsening was defined by a ≥ 1 point increase. Emergent SI was defined by an increase from 0 at baseline to ≥ 1 during treatment. Results: Of the 1909 participants with baseline SI, 57% experienced improvement in SI by their first post-baseline visit and 5% worsened. By the final visit, 74% experienced improvement and 4% worsened. Of 1721 participants without baseline SI, 7% experienced emergence by the first postbaseline visit. Of these, 63% had no SI at their final visit. Major risk factors for treatment-emergent SI at the first treatment visit were drug abuse, severe depression and melancholic features. Limitations: Main limitations are lack of a comparison group to help pinpoint whether citalopram treatment added risk or protection, a placebo group to determine whether changes in SI were related to illness factors, medication effects or other factors, and more detailed and validated measures of SI. Conclusions: SI and behaviors, core features of MDD, wax and wane in intensity before, during, and perhaps after treatment. It is clinically important to understand risk factors, maintain careful surveillance and treat as vigorously as necessary to attain remission.

AB - Background: Untreated major depressive disorder (MDD) is a major risk factor for suicide, but some data suggest antidepressants may be associated with increased suicidal ideation (SI) in some depressed patients. The purpose of this study was to determine whether, and in whom, treatment of MDD is associated with increased or emergent SI. Methods: Patients were treated with Citalopram, 10-60 mg/day for 12-14 weeks. A score > 0 on Item 12 of the Quick Inventory of Depressive Symptomatology - Self-Report indicated the presence of SI. Worsening was defined by a ≥ 1 point increase. Emergent SI was defined by an increase from 0 at baseline to ≥ 1 during treatment. Results: Of the 1909 participants with baseline SI, 57% experienced improvement in SI by their first post-baseline visit and 5% worsened. By the final visit, 74% experienced improvement and 4% worsened. Of 1721 participants without baseline SI, 7% experienced emergence by the first postbaseline visit. Of these, 63% had no SI at their final visit. Major risk factors for treatment-emergent SI at the first treatment visit were drug abuse, severe depression and melancholic features. Limitations: Main limitations are lack of a comparison group to help pinpoint whether citalopram treatment added risk or protection, a placebo group to determine whether changes in SI were related to illness factors, medication effects or other factors, and more detailed and validated measures of SI. Conclusions: SI and behaviors, core features of MDD, wax and wane in intensity before, during, and perhaps after treatment. It is clinically important to understand risk factors, maintain careful surveillance and treat as vigorously as necessary to attain remission.

KW - Major depressive disorder

KW - SSRI

KW - Suicidal ideation

KW - Suicide

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=67650093741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650093741&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2009.01.002

DO - 10.1016/j.jad.2009.01.002

M3 - Article

C2 - 19217668

AN - SCOPUS:67650093741

VL - 117

SP - 63

EP - 73

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 1-2

ER -